Skip to content

OnTrackCF: Engagement, Feasibility, and Acceptability Study

OnTrackCF: Engagement, Feasibility, and Acceptability Study

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07031323
Acronym
OnTrackCF
Enrollment
60
Registered
2025-06-22
Start date
2025-11-20
Completion date
2026-12-31
Last updated
2025-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystic Fibrosis (CF), Cystic Fibrosis - Complete

Keywords

adherence, mHealth, mobile health, digital health, medication adherence, CFTR Modulators

Brief summary

This is a multi-site, nonrandomized study using mixed methods approach to evaluate the feasibility, acceptability, and user engagement of OnTrackCF for adults with Cystic Fibrosis (AWCF).

Interventions

BEHAVIORALOnTrackCF

OnTrackCF is a mHealth application co-developed with Upstream Dream. It is designed specifically to track and support adherence to CFTR modulator therapy. The app allows users to track their modulator intake and disease symptoms while supporting their adherence goals using Behavioral Change Techniques (BCTs) with empirical evidence of efficacy. The BCTs are administered primarily in the form of messages designed to deliver specific BCTs. The app sends up to 3 adherence support messages per day and provides detailed data to the user about their adherence levels, adherence goals, and disease symptoms. This process will continue until we reach an N=60 AWCF enrolled OR demonstrate that we have achieved 12 weeks of sustained user engagement with the app.

Sponsors

Cystic Fibrosis Foundation
CollaboratorOTHER
Johns Hopkins University
CollaboratorOTHER
University of Alabama at Birmingham
CollaboratorOTHER
Boston Children's Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Diagnosed with CF 2. 18+ years of age 3. Prescribed a CFTR modulator therapy to be taken twice a day 4. Can speak and read English 5. Have regular access to an iOS or Android tablet or smartphone with internet access.

Exclusion criteria

1\) Any situation, in the opinion of the Investigator, that would compromise the safety of the patient or the quality of the data

Design outcomes

Primary

MeasureTime frameDescription
System Usability Survey (SUS)through study completion, projected to be 1 yearBy the last round of testing, the System Usability Survey (SUS) will have a median score of 75%.
Intervention Feasibility and Acceptability (iFAQ)through study completion, projected to be 1 yearBy the last round of testing, the Intervention Feasibility and Acceptability (iFAQ) OnTrackCF scales (Engagement, Feasibility, Acceptability, Usefulness, and Satisfaction) will each have a median score of ≥4 (out of 5).

Secondary

MeasureTime frameDescription
Onboarding Completionthrough study completion, projected to be 1 yearBy the last round of testing, 90% of participants will complete the app onboarding process.
Engagement with app featuresthrough study completion, projected to be 1 yearBy the last round of testing, 70% of onboarded participants will engage with at least one app feature at least once during each week of their study period.

Countries

United States

Contacts

Primary ContactEmma M McWilliams, BA
emma.mcwilliams@childrens.harvard.edu617-355-7534
Backup ContactCallie Bacon, MPH
callie.bacon@childrens.harvard.edu617-919-7696

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026